A successful treatment strategy includes analyzing process and identifying missed eligible patients 24,25

Examine discharge data 
Review files of patients with a discharge diagnosis of AIS

Identify missed eligible patients
Determine eligibility according to Activase prescribing information

Compile reasons for non-treatment
Analyze trends for non-treatment of missed eligible patients

Share findings at regular team meetings
Develop strategies to help identify and treat all eligible patients

Execute quality improvement strategies
Continually track performance and outcomes, refine strategies

Frequent causes for slower treatment with Activase include difficulties in determining patient eligibility, delayed diagnoses, and in-hospital delays, which can add over 25 minutes to the door-to-needle time and negatively impact patient outcomes.

BASED ON YOUR METRICS, WHAT IS THE MOST COMMON REASON FOR NOT TREATING WITH ACTIVASE?

Analyze process

Analyze outcomes

DID YOU KNOW?

  • Evaluating and improving processes, such as door-to-needle time, may lead to higher rates of Activase treatment of appropriate patients. 2,15
  • Hospitals are constantly striving to improve their stroke process. Review the case studies presented in this section to learn more.